We thus confirmed the establishment of a tumour‐bearing surrogate rat model, in which we demonstrated restriction of syngeneic tumour growth by rat IgE and IgG2b antibodies, and showed enhanced efficacy of rMOv18 IgE compared with IgG2b. This evidence concerns the gene IGHE and neoplasm.